Perelman Center for Advanced Medicine

More Aggressive Treatment Doesn't Impact Quality of Life for Metastatic Colorectal Cancer Patients, According to New Study in JNCCN

Retrieved on: 
Thursday, October 12, 2023
Neoplasm, Quality of life, CAPOX, Max Healthcare, Penn Medicine Princeton Medical Center, Bevacizumab, Risk, Radiation, EORTC, SAE, Șaeș, Survival, Outline of health sciences, University, Disease, FOLFOX, Patient, Quality of life (healthcare), FACP, University of Pennsylvania Health System, Fatigue, Medicine, Journal of the National Comprehensive Cancer Network, National Comprehensive Cancer Network, Overalls, Face, Perelman Center for Advanced Medicine, Research, Pharmaceutical industry, Nursing, Medical imaging, Life, MD

PLYMOUTH MEETING, Pa., Oct. 12, 2023 /PRNewswire/ -- New research in the October 2023 issue of JNCCN—Journal of the National Comprehensive Cancer Network finds that intensive local-regional treatment to remove as much tumor as possible (known as "debulking"), in addition to standard systemic therapy, does not impact overall quality of life significantly for people with metastatic colorectal cancer.

Key Points: 
  • Significant adverse events were reported in 21% of patients in the standard group and 43% of patients who also received tumor debulking.
  • However, there were no statistical or clinically relevant differences according to patient-reported outcomes for overall health-related quality of life or fatigue.
  • "This could mean that the negative impact of complications on quality of life is temporary and eventually balances out with a decrease in tumor-related symptoms after treatment.
  • "Given the considerable amount of complications from local treatment, we had expected to see a bigger impact on overall and persistent quality of life in the experimental group.

Independence Blue Cross and The Colorectal Cancer Alliance Launch 45+ Reasons Campaign to Support Colorectal Cancer Prevention

Retrieved on: 
Tuesday, August 8, 2023
Survival rate, Independence Blue Cross, Perelman School of Medicine at the University of Pennsylvania, Partnership, University, Wellness, Health equity, Cancer, Large intestine, African Americans, Colorectal Cancer Alliance, Penn Medicine Rittenhouse, Black, Organization, Perelman Center for Advanced Medicine, Community Alliance, Incidence, Colorectal cancer, Development, MD, Pennsylvania Department of Aging, Risk, Salix Pharmaceuticals, Child, Colonoscopy, Cycle, Diversity, Radio, University of Pennsylvania Health System, Mortality, American Cancer Society, USPSTF, Willow, Pennsylvania Department of Health, Social media, Disease, Pharmaceutical industry, Mobile phone, Vaccine, Independence, Medicine

PHILADELPHIA, Aug. 8, 2023 /PRNewswire/ -- Independence Blue Cross (Independence) and the Colorectal Cancer Alliance (the Alliance) announced the launch of 45+ Reasons, a campaign to get more than 5,000 Black Philadelphians ages 45-75 screened for colorectal cancer to reduce the significantly higher incidence and mortality rates of Black Americans. The campaign supports the Cycles of Impact initiative launched by Independence and the Alliance in 2022.

Key Points: 
  • To ensure that the colorectal cancer prevention and screening messages reach those most at risk, the Alliance is launching a compelling new awareness campaign called 45+ Reasons.
  • The community engagement, social media, and advertising campaign aims to instill much-needed trust in the healthcare system with fact-based support for colorectal cancer as a preventable cancer.
  • One way we are addressing this is through this partnership with the Colorectal Cancer Alliance to reduce gaps in colorectal cancer screening rates among Black Philadelphians, who are disproportionately impacted by colorectal cancer."
  • "As the largest nonprofit organization solely committed to ending colorectal cancer, the Alliance is uniquely positioned to lead this bold health intervention," said Michael Sapienza, CEO of the Colorectal Cancer Alliance.

THE PANCREATIC CANCER ACTION NETWORK (PANCAN) ANNOUNCES NEW SCIENTIFIC AND MEDICAL ADVISORY BOARD LEADERS AND MEMBERS

Retrieved on: 
Tuesday, July 18, 2023
Memorial Sloan Kettering Cancer Center, Pancreatic cancer, Perelman School of Medicine at the University of Pennsylvania, University, MBA, Oncology, Research, Biomarker, Doctor of Philosophy, Associate, II, Cancer, Perelman Center for Advanced Medicine, Student, Pancreatic Cancer Action Network, MD, Patient, Physician, Nursing, Lustgarten Foundation for Pancreatic Cancer Research, Division, JD, MSK, University of Pennsylvania Health System, Knowledge, III, Caregiver, Chair, Pharmaceutical industry, Medicine

LOS ANGELES, July 18, 2023 /PRNewswire/ -- The Pancreatic Cancer Action Network (PanCAN), a leading nonprofit in the fight against pancreatic cancer, proudly announces the addition of fourteen new members to its Scientific and Medical Advisory Board (SMAB), as well as the elevation of current SMAB members Eileen M. O'Reilly, MD, of Memorial Sloan Kettering Cancer Center (MSK) and Gregory Beatty, MD, PhD to the roles of Chair and Vice Chair, respectively.  

Key Points: 
  • PanCAN's SMAB is comprised of leading scientists, clinicians and healthcare professionals who specialize in pancreatic cancer from institutions across the United States.
  • "PanCAN is critically important to the field for many reasons, including its extensive outreach, scientific rigor, and support for the clinical and research pancreatic cancer community.
  • "This community is vital to the fight against pancreatic cancer, the sharing of knowledge, and the fostering of new ideas.
  • New members joining the PanCAN SMAB include:
    Additionally, members whose terms have ended are:

Fujitsu launches new cloud-based platform for healthcare sector in Japan, promoting personalized healthcare and drug development

Retrieved on: 
Tuesday, March 28, 2023
Insurance, Allergy, Ministry of Internal Affairs and Communications, Drug development, Information system, Process safety management, MHLW, Health informatics, Internet of things, Health Level Seven International, Communication, Internal affairs, Microsoft, FHIR, Research, Doctor of Philosophy, Problem-Oriented Medical Information System, Behavior, Sapporo Medical University, Development, Healthy Living, Data analysis, MD, Patient, Collection, Health Level 7, Diagnosis, Azure, HL7, AI, Perelman Center for Advanced Medicine, Security Technical Implementation Guide, Education, Health information exchange, Disease, Pharmaceutical industry, Medical device, Medical imaging, Nursing, Health care, Life, Health, Fujitsu

Fujitsu will offer the new platform to medical institutions and pharmaceutical companies in Japan starting March 28, 2023.

Key Points: 
  • Fujitsu will offer the new platform to medical institutions and pharmaceutical companies in Japan starting March 28, 2023.
  • "Microsoft is utilizing cloud services and AI technologies in the healthcare field and promoting the next generation standards framework HL7 FHIR.
  • Health Level Seven, Inc. is an organization dedicated to developing and promoting standards for healthcare information.
  • Health Level Seven, Inc. is an organization dedicated to developing and promoting standards for healthcare information.

Akamis Bio, Parker Institute for Cancer Immunotherapy, and Cancer Research Institute Announce Expanded Partnership to Advance Novel Treatments for Pancreatic Cancer

Retrieved on: 
Thursday, February 16, 2023
Health, Genetics, Science, Research, Clinical Trials, B cell, APC, CRI, CD40, Trial of the century, Therapy, Perelman Center for Advanced Medicine, Cancer, Safety, HIV disease progression rates, Lymph, Neoplasm, Cancer Research Institute, Immune system, University of Pennsylvania Health System, Antibody, Disease, Partnership, Serum, Bio, Pancreatic cancer, Pharmaceutical industry, Vaccine

The NG-350A combination therapy will be part of cohort C in REVOLUTION, a platform clinical study investigating novel therapeutic combinations for the treatment of previously untreated metastatic pancreatic cancer.

Key Points: 
  • The NG-350A combination therapy will be part of cohort C in REVOLUTION, a platform clinical study investigating novel therapeutic combinations for the treatment of previously untreated metastatic pancreatic cancer.
  • Once activated, APCs recruit T cells into the vicinity of the tumor to deliver a potent anti-tumor immune response.
  • NG-350A has the potential for use as both a monotherapy and in combination with other immuno-oncology agents.
  • “Pancreatic cancer is one of the most complex and difficult to treat cancers.

Independence Blue Cross Launches Advanced Network for Gene-Based Therapeutics

Retrieved on: 
Thursday, January 26, 2023
Safety, Therapy, Independence Blue Cross, DSM-IV codes, University of Pennsylvania Health System, Health marketing, Diagnosis, Advanced Network and Services, Transplant, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Partnership, Penn Medicine Princeton Medical Center, CHOP, Hospital, Cell therapy, Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Paratriathlon, Health care, Perelman Center for Advanced Medicine, Patient, Quality of life, Food, Pharmaceutical industry, Nursing, Independence

PHILADELPHIA, Jan. 26, 2023 /PRNewswire/ -- Independence Blue Cross (Independence) today announced the launch of its Advanced Network for Gene-Based Therapeutics, which will be effective March 1, 2023. The new network is designed to help members access potentially life-changing gene-based therapies from best-in-class health care providers that have demonstrated an ability to exceed quality, safety, and value benchmarks in administering gene-based therapies. These treatments provide fresh hope for patients with inherited rare genetic conditions, including a form of blindness and severe neurological and blood diseases.

Key Points: 
  • PHILADELPHIA, Jan. 26, 2023 /PRNewswire/ -- Independence Blue Cross (Independence) today announced the launch of its Advanced Network for Gene-Based Therapeutics, which will be effective March 1, 2023.
  • The providers in Independence's Advanced Network for Gene-Based Therapeutics include Penn Medicine and Children's Hospital of Philadelphia (CHOP).
  • We look forward to continuing this collaboration and leading the way in providing the best possible treatments for children with genetic diseases as part of the Advanced Network for Gene-Based Therapeutics."
  • The dedicated team is trained to answer member questions, empower member decision-making, and facilitate connections between members and the specialists on the Advanced Network care team.

ONI and the University of Pennsylvania Start Research Collaboration to Identify Unique Biomarkers and Characteristics to Guide Next Generation CAR-T Development

Retrieved on: 
Tuesday, October 11, 2022
Stem Cells, Biotechnology, Health, Pharmaceutical, Biometrics, Oncology, Other Science, Medical Devices, Research, Science, Clinical Trials, LinkedIn, Disease, Therapy, University of Oxford, Patient, ACC, HQ, Research, Twitter, University, MD, Toxicity, CEO, Oxford Nanoimaging, Safety, University of Pennsylvania, Nanoparticle, Center, Perelman Center for Advanced Medicine, FDA, Biomarker, Medical imaging

ONI , a single-molecule imaging platform biotech, today announced a research collaboration with the University of Pennsylvania, one of the true pioneers of CAR-T (chimeric antigen t-cell) research and clinical trials.

Key Points: 
  • ONI , a single-molecule imaging platform biotech, today announced a research collaboration with the University of Pennsylvania, one of the true pioneers of CAR-T (chimeric antigen t-cell) research and clinical trials.
  • The collaboration aims to enhance the understanding of CAR-T therapies using super-resolution microscopy, identifying predictive biomarkers and characteristics related to CAR-T treatment efficacy and safety, with the goal of improving patient outcomes.
  • ONIs flagship product, the Nanoimager, will allow these researchers to visualize living cells and track how single molecules interact.
  • For more information, visit oni.bio and follow ONI on Twitter @oniHQ and LinkedIn @ONI.

Rocket VR Health Partners with Penn Medicine's Abramson Cancer Center to Study the Use of VR in Patients Undergoing Radiation Therapy

Retrieved on: 
Thursday, August 18, 2022
Meditation, Multimedia, Lists of Palestinian rocket attacks on Israel, Mental health, HTC, Penn, Technology, Cancer, Radiation therapy, Department, Health, Virtual reality, Patient, Perelman School of Medicine at the University of Pennsylvania, View, Therapy, Perelman Center for Advanced Medicine, COO, Nature, Mindfulness, Survivor, Penn Medicine Princeton Medical Center, MD, VR, University of Pennsylvania Health System, Medical imaging

BOSTON, Aug. 18, 2022 /PRNewswire/ -- Rocket VR Health, a digital therapeutics company developing immersive therapy programs, is partnering with Penn Medicine's Abramson Cancer Center to explore the use of virtual reality (VR) technology in cancer patients undergoing radiation therapy.

Key Points: 
  • BOSTON, Aug. 18, 2022 /PRNewswire/ -- Rocket VR Health , a digital therapeutics company developing immersive therapy programs, is partnering with Penn Medicine's Abramson Cancer Center to explore the use of virtual reality (VR) technology in cancer patients undergoing radiation therapy.
  • Rocket VR's immersive meditation program will be administered as part of a feasibility study with 25 patients prior to receiving daily treatments, utilizing the HTC VIVE Flow VR headset.
  • The imagery and sounds experienced are designed to create an immersive environment by making use of mindfulness meditation in nature.
  • Rocket VR Health is developing virtual reality digital therapeutics to address unmet mental health needs in cancer patients and survivors.

HyBryte™ Phase 3 FLASH Study for the Treatment of Cutaneous T-Cell Lymphoma Published in JAMA Dermatology

Retrieved on: 
Wednesday, July 20, 2022
American Medical Association, JAMA Dermatology, JAMA, University, Perelman Center for Advanced Medicine, Lead, Dermatologic Clinics, Fluorescent lamp, NASDAQ, Hospital, Quality of life, Journal, Company, MD, Medical director, Patient, FLASH, Hospital of the University of Pennsylvania, T-cell lymphoma, Pharmaceutical industry, Dermatology, CTCL

The published findings demonstrate that HyBryte treatment statistically significantly reduced lesion size, with the treatment response further improving over successive 6-week treatment cycles.

Key Points: 
  • The published findings demonstrate that HyBryte treatment statistically significantly reduced lesion size, with the treatment response further improving over successive 6-week treatment cycles.
  • JAMA Dermatology is an international peer-reviewed journal published online weekly and in print/ online issue 12 times a year.
  • JAMA Dermatologyis a member of the JAMA Network family of journals, which includesJAMA, 11 JAMA Network specialty journals, andJAMA Network Open.
  • In the first double-blind treatment cycle, 116 patients received HyBryte treatment (0.25% synthetic hypericin) and 50 received placebo treatment of their index lesions.

Pennsylvania US Navy Veterans Mesothelioma Advocate Urges a Navy Veteran with Mesothelioma Anywhere in Pennsylvania to Get Serious About Compensation and Call Danziger & De Llano for Better Results-That May Be Millions

Retrieved on: 
Tuesday, June 14, 2022
Upper Darby Township, Delaware County, Pennsylvania, Navy, UPMC Hillman Cancer Center, United States Navy, Perelman Center for Advanced Medicine, ICEX: US Navy Mission in Arctic, Penns, University, Veteran, National, National Institutes of Health Director's Pioneer Award, Incidence, Llano, United States Navy Veterans Association, Asbestos, Family, Cancer, Mesothelioma, Real estate, Oil

"To ensure a Navy Veteran with mesothelioma in Pennsylvania or anywhere in the nation receives the best possible compensation we have endorsed, and we recommend the remarkable legal team at the law firm ofDanziger&De Llano.

Key Points: 
  • "To ensure a Navy Veteran with mesothelioma in Pennsylvania or anywhere in the nation receives the best possible compensation we have endorsed, and we recommend the remarkable legal team at the law firm ofDanziger&De Llano.
  • As the representatives atDanziger&De Llanoare always happy to discuss at 800-864-4000-mesothelioma compensation for a Navy Veteran with this rare cancer might be millions of dollars.
  • https://meso.dandell.com/
    The Pennsylvania US Navy Veterans Mesothelioma Advocate is focused on the best possible financial compensation results for a Navy Veteran with mesothelioma in Philadelphia, Pittsburgh, Allentown, Eire, Upper Darby, Reading, Scranton, Bethlehem or anywhere in Pennsylvania.
  • About one third of all US citizens diagnosed with mesothelioma each year are Veterans of the US Navy.